Bacillus Calmette-Guerin (BCG) revaccination was discontinued in Finland in 1990. The objective of this study was to assess the impact of BCG revaccination of tuberculin-negative school-children in prevention of tuberculosis. The tuberculosis cases in 1990-1995 were calculated among age cohorts born 1979-1984 and no longer covered by the BCG revaccination program. Corresponding data were collected for comparison from the period of revaccination in 1980-1985 among age cohorts born in 1969-1974. The National Tuberculosis Register was reviewed in order to observe the tuberculosis trend since 1980 in the age groups of 10-14 and 15-19 yr. Three cases of tuberculosis have been registered among non-BCG-revaccinated children during 6 yr after discontinuation of the program, i.e., 2.23 cases (95% CI 0.72 to 6.90) per million person yr. The control group revealed five cases, 3.78 (95% CI 1.57 to 9.07) per million person yr. The relative risk of tuberculosis in non-BCG-revaccinated children is 0.59 (95% CI 0.14 to 2.47) compared with the control group. The incidence of tuberculosis has continued to decline among adolescents since 1980. The follow-up data confirm that the cessation of BCG revaccination program had no effect on the continuing overall decline of tuberculosis in Finland. The efficacy of BCG revaccination seems to be low or nonexistent in countries with low tuberculosis incidence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1164/ajrccm.157.4.9706037 | DOI Listing |
Infect Genet Evol
December 2024
Department of Life Sciences, Sharda School of Basic Sciences and Research, Sharda University, Knowledge Park III, Greater Noida, Uttar Pradesh 201306, India. Electronic address:
The BCG vaccine represents a significant milestone in the prevention of tuberculosis (TB), particularly in children. Researchers have been developing recombinant BCG (rBCG) variants that can trigger lasting memory responses, thereby enhancing protection against TB in adults. The breakdown of immune surveillance is a key link between TB and other communicable and non-communicable diseases.
View Article and Find Full Text PDFJ Transl Med
December 2024
Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Hubei Key Laboratory of Drug Target Research and Pharmacodynamic Evaluation, Huazhong University of Science and Technology, Wuhan, China.
BMC Public Health
November 2024
REMS Consultancy Services Limited, Sekondi-Takoradi, Western Region, Ghana.
Vaccines (Basel)
October 2024
Instituto de Agrobiotecnología y Biología Molecular (IABiMo), UEDD CONICET-INTA, Centro de Investigación en Ciencias Veterinarias y Agronómicas (CICVyA)-CNIA, Hurlingham 1686, Buenos Aires Province, Argentina.
Lancet Glob Health
November 2024
Immunomodulation and Vaccines Focus Area, Vaccine Research Theme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.
Background: Immune responses induced by several important vaccines differ between populations, with reduced responses in low-income and rural settings compared with high-income and urban settings. BCG immunisation boosts immune responses to some unrelated vaccines in high-income populations. We aimed to test the hypothesis that BCG revaccination can enhance responses to unrelated vaccines in Ugandan schoolchildren.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!